Issue 9 - Mar 5, 2021
  • Conversation with The Cancer Letter

    Not for sale: Fox Chase Cancer Center

    Last year, Fox Chase Cancer Center stood poised to make history by becoming the first NCI-designated cancer center to be sold on open market. The Cancer Letter spoke with Richard I. Fisher, president, CEO and director of Fox Chase.

  • Three companies withdraw cancer indications for PD-1/PD-L1 drugs in FDA’s “industry-wide evaluation”

    Over the past three months, three pharmaceutical companies voluntarily withdrew three cancer indications for drugs that had previously received accelerated approvals from FDA, but ultimately failed to meet agreed-upon endpoints in confirmatory trials required for regular approvals.

  • NASEM: Reduce cancer drug waste by reformulating development, payments, dosing

    Once an expensive cancer drug is discarded, it’s not worth it for drug developers, health care providers, and payers to recoup its cost, the National Academies of Sciences, Engineering, and Medicine said in a congressionally mandated report.

  • Cancer History Project

    A 25-year retrospective: How NCCN changed the way cancer medicine is practiced—and paid for

    A quarter century ago, on March 3, 1996, in Ft. Lauderdale, the National Comprehensive Cancer Network held a conference—its first.

  • In the Archives

    Women’s History Month: Amy Reed, Carol Fabian

    This column in The Cancer Letter features the latest posts to the Cancer History Project by our growing list of contributors.

  • In Brief

    • Hans Clevers receives 2021 Pezcoller Foundation-AACR award
    • Sarah Hawley named associate director education, training programs at UMich Rogel Cancer Center
    • Lilli Petruzzelli named SVP of early clinical development at Genentech’s gRED
    • Brian Faith named VP of communications at City of Hope
    • Six early-career cancer researchers receive nearly $3 million total from The Parker Institute for Cancer Immunotherapy
    • Case Comprehensive Cancer Center receives $2.75 million to increase prostate cancer screening in African American men
    • Yale establishes Chênevert Family Brain Tumor Center
  • Funding Opportunities

    DoD prostate cancer research funding opportunity for FY21

    The FY21 Defense Appropriations Act is anticipated to provide funding to the Department of Defense Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.

  • TCCL Logo

  • Clinical Roundup

    • NCCN guidelines for histiocytosis clarify best practices for recently-defined cancers
    • Yale researchers identify T cells active against advanced melanoma
    • UNC Lineberger study: Engineered safety switch curbs severe side effects of CAR T immunotherapy
    • City of Hope researchers investigate checkpoint inhibitor combination for TNBC
    • GO2 Foundation initiates study to improve participation of Black communities in lung cancer clinical trials
  • Drugs & Targets

    • FDA approves lorlatinib for metastatic ALK-positive NSCLC
    • FDA authorizes first robotically-assisted surgical device for performing transvaginal hysterectomy
    • FDA grants accelerated approval to Pepaxto for relapsed or refractory multiple myeloma
    • CHMP recommends approval of Sarclisa + carfilzomib, dexamethasone for relapsed multiple myeloma
    • CHMP tissues positive opinion for Opdivo + Cabometyx as first-line treatment for advanced RCC
    • CHMP recommends approval of dostarlimab for women with recurrent or advanced endometrial cancer
    • Novartis completes in-licensing of tislelizumab
  • NCI Trials

    NCI Trials for March 2021

    The National Cancer Institute approved the following clinical research studies last month. 

Issue 8 - Feb 26, 2021
Issue 7 - Feb 19, 2021